Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 438 out of 166,615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 12,226 | 11,358 |
| Total Cites | 16,593 | 19,892 |
| H-index | 67 | 74 |
| Hm-index | 29 | 31 |
| Number of Single Authored Papers | 98 | 98 |
| Total Cites to Single Authored Papers | 1,263 | 1,400 |
| Number of Single+First Authored Papers | 205 | 205 |
| Total Cites to Single+First Authored Papers | 5,340 | 6,133 |
| Number of Single+First+Last Authored Papers | 332 | 332 |
| Total Cites to Single+First+Last Authored Papers | 6,894 | 7,896 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 12,790 | 14,300 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.39 |
| Self-Citation Percentage |
16.58%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 479 out of 157,372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 13,272 | 11,937 |
| Total Cites | 14,904 | 17,963 |
| H-index | 61 | 71 |
| Hm-index | 28 | 29 |
| Number of Single Authored Papers | 94 | 94 |
| Total Cites to Single Authored Papers | 1,166 | 1,296 |
| Number of Single+First Authored Papers | 208 | 208 |
| Total Cites to Single+First Authored Papers | 4,914 | 5,675 |
| Number of Single+First+Last Authored Papers | 333 | 333 |
| Total Cites to Single+First+Last Authored Papers | 6,332 | 7,291 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 11,537 | 12,945 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.39 |
| Self-Citation Percentage |
17.03%
|
|
Steensma, David P.
Novartis Institutes for BioMedical Research, Inc.,
United States
2023 Rank: 14,394
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 532 out of 147,556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 14,394 | 13,048 |
| Total Cites | 13,162 | 15,915 |
| H-index | 58 | 66 |
| Hm-index | 26 | 28 |
| Number of Single Authored Papers | 92 | 92 |
| Total Cites to Single Authored Papers | 1,061 | 1,189 |
| Number of Single+First Authored Papers | 201 | 201 |
| Total Cites to Single+First Authored Papers | 4,456 | 5,183 |
| Number of Single+First+Last Authored Papers | 325 | 325 |
| Total Cites to Single+First+Last Authored Papers | 5,743 | 6,658 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 10,301 | 11,593 |
| Ratio of Total Citations to Distinct Citing Papers | 1.28 | 1.37 |
| Self-Citation Percentage |
17.30%
|
|
Steensma, David P.
Novartis Institutes for BioMedical Research, Inc.,
United States
2022 Rank: 16,104
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 606 out of 138,599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16,104 | 14,212 |
| Total Cites | 11,397 | 13,800 |
| H-index | 53 | 61 |
| Hm-index | 25 | 27 |
| Number of Single Authored Papers | 92 | 92 |
| Total Cites to Single Authored Papers | 924 | 1,049 |
| Number of Single+First Authored Papers | 196 | 196 |
| Total Cites to Single+First Authored Papers | 3,964 | 4,649 |
| Number of Single+First+Last Authored Papers | 317 | 317 |
| Total Cites to Single+First+Last Authored Papers | 5,104 | 5,959 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 9,007 | 10,152 |
| Ratio of Total Citations to Distinct Citing Papers | 1.27 | 1.36 |
| Self-Citation Percentage |
17.41%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 625 out of 127,911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16,796 | 15,527 |
| Total Cites | 10,499 | 12,741 |
| H-index | 51 | 57 |
| Hm-index | 24 | 26 |
| Number of Single Authored Papers | 91 | 91 |
| Total Cites to Single Authored Papers | 855 | 966 |
| Number of Single+First Authored Papers | 190 | 190 |
| Total Cites to Single+First Authored Papers | 3,693 | 4,333 |
| Number of Single+First+Last Authored Papers | 310 | 310 |
| Total Cites to Single+First+Last Authored Papers | 4,766 | 5,564 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 8,380 | 9,472 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.35 |
| Self-Citation Percentage |
17.60%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 738 out of 108,509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 20,744 | 18,552 |
| Total Cites | 8,660 | 10,626 |
| H-index | 45 | 49 |
| Hm-index | 22 | 24 |
| Number of Single Authored Papers | 88 | 88 |
| Total Cites to Single Authored Papers | 689 | 794 |
| Number of Single+First Authored Papers | 182 | 182 |
| Total Cites to Single+First Authored Papers | 3,194 | 3,802 |
| Number of Single+First+Last Authored Papers | 294 | 294 |
| Total Cites to Single+First+Last Authored Papers | 4,098 | 4,853 |
| Composite Score | 3 | 4 |
| Number of Distinct Citing Papers | 7,005 | 7,974 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.33 |
| Self-Citation Percentage |
18.50%
|
|
Trending Researchers
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.